

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ascletis Pharma Inc.**

**歌禮製藥有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1672)**

## **VOLUNTARY ANNOUNCEMENT**

### **ASCLETIS TO PRESENT DATA ON MULTIPLE PROGRAMS AT THE 33RD EUROPEAN CONGRESS ON OBESITY (ECO 2026)**

This announcement is made by Ascletis Pharma Inc. (the “**Company**” or “**Ascletis**”, together with its subsidiaries, the “**Group**”) on a voluntary basis for the purpose of keeping the shareholders of the Company and potential investors abreast of the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announces poster presentations highlighting multiple programs at the 33rd European Congress on Obesity (ECO 2026), taking place May 12-15, 2026 in Istanbul, Türkiye.

The presentations include a poster on the Phase I data of ASC47, an adipose-targeting thyroid hormone receptor beta (THR $\beta$ ) agonist for muscle-preserving weight loss, which, in combination with semaglutide, demonstrated up to 111.8% greater relative weight loss in participants with obesity compared to semaglutide monotherapy, and a poster on the preclinical data of ASC36, a once-monthly next-generation amylin receptor agonist peptide, which demonstrated 32-day average observed half-life, 6-fold longer than petrelintide, in non-human primate (NHP) model and 91% more relative weight loss than petrelintide in diet-induced obese (DIO) rat model.

#### **Presentation details**

**Title:** ASC47 in Combination with Semaglutide Demonstrated Up to 111.8% Greater Relative Weight loss in Participants with Obesity Compared to Semaglutide Monotherapy

**Session:** Track 4: Obesity Management and Intervention (PO4.264)

**Date/Time:** Thursday, 14 May, 2026, 18:00-19:15 TRT

**Title:** ASC36, a Once-Monthly Next-Generation Amylin Receptor Agonist Peptide, Demonstrated 32-day Average Observed Half-life, 6-fold Longer than Petrelintide, in NHP Model and 91% More Relative Weight Loss than Petrelintide in DIO Rat Model

**Session:** Track 4: Obesity Management and Intervention (PO4.270)

**Date/Time:** Thursday, 14 May, 2026, 18:00-19:15 TRT

**Title:** ASC35, a Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist Peptide, Demonstrated 14-day Average Observed Half-life, 6-fold Longer than Tirzepatide, in NHP Model and 71% More Relative Weight Loss than Tirzepatide in DIO Mouse Model

**Session:** Track 4: Obesity Management and Intervention (PO4.263)

**Date/Time:** Thursday, 14 May, 2026, 18:00-19:15 TRT

Additional information about the ECO 2026 is available at <https://eco2026.org/>.

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** We cannot guarantee that we will be able to ultimately develop, manufacture and/or commercialize ASC47, ASC36 and/or ASC35 successfully.

By order of the Board  
**Ascleto Pharma Inc.**  
歌禮製藥有限公司  
**Jinzi Jason WU**  
*Chairman*

Hong Kong  
May 6, 2026

*As at the date of this announcement, the Board comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.*